Table 2.
Evaluating Interactions of Vitamin D Related Genotypes and Finasteride with Prostate Cancer in the Prostate Cancer Prevention Trial, Stratified by Race.
| Caucasian | African American | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N case/control | N case/control | |||||||||||
| Allele | Number of minor alleles | OR (95% CI)1 | Number of minor alleles | OR (95% CI)1 | ||||||||
| Gene | rs number | Treatment Arm | Major | Minor | 0 | 1 | 2 | 0 | 1 | 2 | ||
| VDR | rs1544410 | Finasteride | G | A | 156/129 | 212/189 | 75/97 | 0.83 (0.69–1.01) | 8/37 | 11/38 | 1/6 | 1.11 (0.48–2.56) |
| Placebo | 222/233 | 301/315 | 100/101 | 1.00 (0.85–1.18) | 8/28 | 13/18 | 5/3 | 2.48 (1.07–5.78) | ||||
| VDR | rs11568820 | Finasteride | G | A | 284/259 | 139/146 | 20/13 | 1.01 (0.79–1.28) | 2/6 | 6/27 | 11/48 | 0.88 (0.40–1.92) |
| Placebo | 405/418 | 206/207 | 22/26 | 1.01 (0.83–1.24) | 2/5 | 9/14 | 16/30 | 1.13 (0.49–2.59) | ||||
| VDR | rs757343 | Finasteride | G | A | 349/325 | 84/81 | 7/4 | 0.99 (0.73–1.35) | 17/69 | 3/11 | 0/1 | 1.12 (0.29–4.35) |
| Placebo | 482/489 | 138/153 | 8/8 | 0.93 (0.73–1.18) | 24/41 | 3/7 | 0.93 (0.19–4.45) | |||||
| VDR | rs11574143 | Finasteride | G | A | 369/347 | 71/68 | 4/3 | 0.97 (0.69–1.37) | 18/66 | 2/13 | 0/2 | 0.50 (0.11–2.37) |
| Placebo | 523/525 | 107/122 | 3/6 | 0.84 (0.64–1.10) | 23/40 | 4/9 | 1.22 (0.29–5.09) | |||||
| GC | rs7041 | Finasteride | C | A | 149/142 | 215/191 | 79/81 | 0.97 (0.80–1.17) | 2/6 | 5/23 | 13/52 | 0.89 (0.40–1.95) |
| Placebo | 186/199 | 312/314 | 127/139 | 1.00 (0.85–1.17) | 0/1 | 10/21 | 17/26 | 1.22 (0.43–3.47) | ||||
| GC | rs222014 | Finasteride | G | A | 339/339 | 93/74 | 8/4 | 1.36 (1.00–1.86)+** | 12/64 | 7/16 | 0/1 | 1.83 (0.65–5.10) |
| Placebo | 508/509 | 117/134 | 7/9 | 0.84 (0.65–1.08)** | 18/44 | 9/4 | 0/1 | 3.16 (0.92–10.89) | ||||
| GC | rs222016 | Finasteride | A | G | 296/310 | 131/99 | 15/10 | 1.37 (1.06–1.79)+ ** | 2/20 | 8/43 | 8/17 | 2.12 (0.92–4.88) |
| Placebo | 455/460 | 166/169 | 11/24 | 0.85 (0.68–1.05)** | 3/12 | 16/24 | 6/11 | 1.26 (0.56–2.87) | ||||
| GC | rs705117 | Finasteride | A | G | 318/307 | 110/95 | 14/14 | 1.03 (0.79–1.34) | 1/11 | 10/31 | 9/39 | 1.10 (0.52–2.30) |
| Placebo | 466/466 | 152/171 | 14/16 | 0.91 (0.73–1.13) | 7/5 | 12/27 | 8/17 | 0.79 (0.34–1.81) | ||||
| GC | rs2282679 | Finasteride | A | C | 240/223 | 173/163 | 28/33 | 0.94 (0.75–1.17) | 16/66 | 3/14 | 0/1 | 0.72 (0.19–2.72) |
| Placebo | 311/325 | 264/270 | 60/60 | 1.02 (0.86–1.21) | 17/38 | 10/11 | 1.07 (0.32–3.53) | |||||
| GC | rs12512631 | Finasteride | A | G | 175/166 | 223/196 | 43/53 | 0.95 (0.77–1.17) | 10/28 | 7/45 | 2/8 | 0.60 (0.26–1.38) |
| Placebo | 287/313 | 281/267 | 64/72 | 1.05 (0.89–1.24) | 15/23 | 9/21 | 3/5 | 1.12 (0.49–2.57) | ||||
| C10orf88 | rs6599638 | Finasteride | G | A | 132/123 | 219/204 | 87/85 | 0.92 (0.76–1.12) | 3/37 | 9/39 | 7/5 | 4.88 (1.96–12.13)+ ** |
| Placebo | 179/206 | 304/309 | 141/129 | 1.11 (0.95–1.30) | 9/23 | 13/18 | 5/8 | 1.39 (0.65–2.97)** | ||||
| CYP2R1 | rs2060793 | Finasteride | G | A | 170/163 | 211/181 | 62/73 | 0.93 (0.76–1.13) | 8/34 | 11/36 | 1/11 | 0.82 (0.38–1.77) |
| Placebo | 237/249 | 294/304 | 103/99 | 1.02 (0.87–1.20) | 14/24 | 10/22 | 2/3 | 1.68 (0.65–4.35) | ||||
| CYP24A1 | rs2248359 | Finasteride | G | A | 166/148 | 200/197 | 76/74 | 0.97 (0.80–1.17) | 3/14 | 6/35 | 9/32 | 1.29 (0.61–2.73) |
| Placebo | 241/224 | 309/303 | 79/122 | 0.81 (0.69–0.95) | 3/8 | 11/21 | 12/20 | 1.69 (0.75–3.81) | ||||
| CYP24A1 | rs2762942 | Finasteride | A | G | 398/382 | 42/36 | 2/1 | 1.13 (0.72–1.77) | 20/77 | 0/4 | ||
| Placebo | 570/572 | 60/81 | 5/1 | 0.87 (0.62–1.21) | 26/46 | 1/3 | 0.31 (0.02–4.90) | |||||
| CYP24A1 | rs4809958 | Finasteride | A | C | 306/302 | 125/108 | 12/7 | 1.17 (0.89–1.53) | 17/68 | 2/13 | 0.63 (0.12–3.25) | |
| Placebo | 460/466 | 159/174 | 13/13 | 0.96 (0.77–1.20) | 26/41 | 1/8 | 0.17 (0.02–1.77) | |||||
| CYP24A1 | rs6013897 | Finasteride | G | A | 275/260 | 144/141 | 23/16 | 1.04 (0.82–1.31) | 7/50 | 12/25 | 1/6 | 1.80 (0.84–3.83) |
| Placebo | 391/378 | 210/243 | 31/30 | 0.92 (0.76–1.11) | 19/27 | 7/21 | 1/1 | 0.68 (0.24–1.92) | ||||
| CYP24A1 | rs6022999 | Finasteride | A | G | 244/235 | 170/159 | 28/23 | 1.09 (0.87–1.36) | 4/10 | 8/42 | 8/29 | 0.96 (0.46–1.99) |
| Placebo | 364/382 | 238/228 | 31/44 | 0.98 (0.81–1.17) | 3/10 | 15/22 | 9/16 | 1.37 (0.63–2.97) | ||||
| CYP27B1 | rs703842 | Finasteride | A | G | 212/174 | 199/187 | 31/54 | 0.76 (0.62–0.95)+ ** | 10/42 | 10/28 | 0/10 | 0.77 (0.35–1.70) |
| Placebo | 282/303 | 271/279 | 81/67 | 1.10 (0.94–1.30)** | 12/17 | 14/25 | 1/6 | 0.69 (0.29–1.65) | ||||
| DHCR7 | rs1790349 | Finasteride | A | G | 318/295 | 111/116 | 14/6 | 0.98 (0.75–1.29) | 12/53 | 8/23 | 0/5 | 1.01 (0.43–2.41) |
| Placebo | 443/472 | 167/168 | 22/14 | 1.15 (0.93–1.42) | 19/32 | 8/15 | 0/2 | 0.61 (0.20–1.84) | ||||
| NADSYN1 | rs3829251 | Finasteride | G | A | 315/285 | 100/116 | 18/10 | 0.92 (0.71–1.19) | 11/48 | 8/25 | 0/7 | 0.85 (0.37–1.96) |
| Placebo | 442/457 | 159/173 | 21/15 | 1.05 (0.85–1.30) | 16/26 | 11/20 | 0/3 | 0.76 (0.28–2.04) | ||||
| NADSYN1 | rs12785878 | Finasteride | A | C | 250/221 | 159/172 | 33/26 | 0.94 (0.75–1.17) | 2/4 | 8/39 | 10/38 | 0.89 (0.39–2.04) |
| Placebo | 349/350 | 240/251 | 45/52 | 0.98 (0.82–1.16) | 3/3 | 12/18 | 12/28 | 0.77 (0.34–1.76) | ||||
All models adjusted for age, BMI, PSA, and family history of prostate cancer
+
Main effects p-value significant after a within gene Bonferroni adjustment. Significance thresholds among genes were : VDR = 0.013 (4 tests), GC= 0.008 (6 tests), C10corf88 = 0.05 (1 test), CYP2R1 = 0.05 (1 test), CYP24A1 = 0.01 (5 tests), CYP27B1 = 0.05 (1 test), DHCR7= 0.05 (1 test), and NADSYN1 = 0.025 (2 tests).
**
p-interaction<0.05.
1.
Per minor allele